Aardvark Therapeutics, Inc.
AARD
$4.18
-$0.36-7.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.87% | 11.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.10% | 5.65% | |||
| Operating Income | -20.10% | -5.65% | |||
| Income Before Tax | -22.67% | -7.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.67% | -7.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.67% | -7.86% | |||
| EBIT | -20.10% | -5.65% | |||
| EBITDA | -20.11% | -5.66% | |||
| EPS Basic | -22.48% | -7.52% | |||
| Normalized Basic EPS | -22.54% | -7.16% | |||
| EPS Diluted | -22.48% | -7.52% | |||
| Normalized Diluted EPS | -22.54% | -7.16% | |||
| Average Basic Shares Outstanding | 0.15% | 0.32% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||